ACE-2 Antibody (2817M) [Alexa Fluor® 594]

• Reactivity: Hu
• Applications: Flow
• Clone: 2817M
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Alexa Fluor 594

ACE-2 Antibody (2817M) [Alexa Fluor® 594] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Mouse myeloma cell line NS0-derived human ACE-2
  Gln18-Ser740
  Accession # Q9BYF1
• Specificity: Detects human ACE-2 in direct ELISAs.
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity Statement: Protein A or G purified from cell culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 0.25-1 ug/10^6 cells

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.
• Reconstitution Instructions: Reconstitution default not known

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for ACE-2 Antibody (2817M) [Alexa Fluor® 594]

• ACE2
• ACE-2
• ACEH
• ACEHangiotensin I converting enzyme 2
• ACE-related carboxypeptidase
• angiotensin I converting enzyme (peptidyl-dipeptidase A) 2
• angiotensin-converting enzyme 2
• Angiotensin-converting enzyme homolog
• DKFZp434A014
• EC 3.4.17
• EC 3.4.17.23
• Metalloprotease MPROT15

Background

Angiotensin I Converting Enzyme (ACE-2), also called ACEH (ACE homologue), is a dimeric, zinc-dependent metalloprotease of the ACE family that also includes somatic and germinal ACE (1, 2). ACE-2 mRNA is found at high levels in heart, testis, and kidney and at lower levels in a wide variety of tissues (1, 3). ACE-2 is the SARS-CoV and SARS-CoV2 Spike protein receptor in vivo (4-6), functions catalytically as a carboxypeptidase to cleave several substrates including angiotensins I and II, and acts as a partner for B0AT1-family amino acid transporters (1, 2). Through these functions, ACE-2 has been shown to be involved in several diseases including SARS, COVID19, acute lung injury (4, 7), heart disease (8), liver and lung fibrosis (9), inflammatory lung disease (10), and cardiopulmonary disease (11). Full length ACE-2 protein includes an extracellular region composed of a single N-terminal peptidase domain and C-terminal collectrin-like domain (CLD), a transmembrane domain, and a short cytoplasmic tail (12). The N-terminal peptidase region is required for binding to SARS-CoV and SARSCoV2 spike proteins, while the CLD contains a region that promotes dimerization and association with amino acid transporters (2). The peptidase domain contains a long deep cleft that undergoes a large hinge-bending movement at substrate and inhibitor binding (12).  Classical ACE inhibitors such as captopril and lisinopril do not inhibit ACE-2 activity and inhibitors of ACE-2 do not inhibit ACE activity (13).

1. Kuba, K. et al. (2010) Pharmacol. Ther. 128:119.
2. Yan, et al. (2020) Science 367:1444.
3. Tipnis, S.R. et al. (2000) J. Biol. Chem. 275:33238.
4. Kuba, K. et al. (2005) Nature Med. 11:875.
5. Hoffmann, M. et al. (2020) Cell.181:1.
6. Wrapp, et al. (2020) Science 367:1260.
7. Imai, Y. et al. (2005) Nature 436:112.
8. Huang, L. et al. (2003) J. Biol. Chem. 278:15532.
9. Schrom, E. et al. (2017) Mol. Therapy Nuc. Acid 7:350.
10. Jia, H. et al. (2016) Shock. 46:239.
11. Cole-Jeffrey, C.T. et al. (2015) J. Cadiovasc. Pharmacol. 66:540.
12. Towler, P. et al. (2004) J. Biol. Chem. 279:17996.
13. Crackower, M.A. et al. (2002) Nature 417:822.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q9BYF1()